The reasonwhy for these results, the tumor cells may be more vulnerable to theDVL immune attack after exposure to DTX therapy.58,59 Results from ELISA showed that after treatment of the PD-L1 levelon the MDA-MB-231 cells, the supernatant was higher than that of MCF-7cells. The gene discussed is CD274; the disease is neoplasm.